• Je něco špatně v tomto záznamu ?

Molecular Pathology of ALS: What We Currently Know and What Important Information Is Still Missing

N. Jankovska, R. Matej

. 2021 ; 11 (8) : . [pub] 20210729

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024274

Grantová podpora
00064165 MH CZ - DRO: Conceptual Development of Research Organization, the General University Hospital, Prague
00064190 MH CZ - DRO: Conceptual Development of Research Organization, the Thomayer University Hospital, Prague
NV19-04-00090 the Grants Agency of the Ministry of Health
NV18-04-00179 the Grants Agency of the Ministry of Health
GAUK 142120 Univerzita Karlova v Praze
Project Progress Q27/LF1 Univerzita Karlova v Praze

Despite an early understanding of amyotrophic lateral sclerosis (ALS) as a disease affecting the motor system, including motoneurons in the motor cortex, brainstem, and spinal cord, today, many cases involving dementia and behavioral disorders are reported. Therefore, we currently divide ALS not only based on genetic predisposition into the most common sporadic variant (90% of cases) and the familial variant (10%), but also based on cognitive and/or behavioral symptoms, with five specific subgroups of clinical manifestation-ALS with cognitive impairment, ALS with behavioral impairment, ALS with combined cognitive and behavioral impairment, the fully developed behavioral variant of frontotemporal dementia in combination with ALS, and comorbid ALS and Alzheimer's disease (AD). Generally, these cases are referred to as amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD). Clinical behaviors and the presence of the same pathognomonic deposits suggest that FTLD and ALS could be a continuum of one entity. This review was designed primarily to compare neuropathological findings in different types of ALS relative to their characteristic locations as well as the immunoreactivity of the inclusions, and thus, foster a better understanding of the immunoreactivity, distribution, and morphology of the pathological deposits in relation to genetic mutations, which can be useful in specifying the final diagnosis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024274
003      
CZ-PrNML
005      
20211013134007.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/diagnostics11081365 $2 doi
035    __
$a (PubMed)34441299
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Jankovska, Nikol $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, 140 00 Prague, Czech Republic
245    10
$a Molecular Pathology of ALS: What We Currently Know and What Important Information Is Still Missing / $c N. Jankovska, R. Matej
520    9_
$a Despite an early understanding of amyotrophic lateral sclerosis (ALS) as a disease affecting the motor system, including motoneurons in the motor cortex, brainstem, and spinal cord, today, many cases involving dementia and behavioral disorders are reported. Therefore, we currently divide ALS not only based on genetic predisposition into the most common sporadic variant (90% of cases) and the familial variant (10%), but also based on cognitive and/or behavioral symptoms, with five specific subgroups of clinical manifestation-ALS with cognitive impairment, ALS with behavioral impairment, ALS with combined cognitive and behavioral impairment, the fully developed behavioral variant of frontotemporal dementia in combination with ALS, and comorbid ALS and Alzheimer's disease (AD). Generally, these cases are referred to as amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD). Clinical behaviors and the presence of the same pathognomonic deposits suggest that FTLD and ALS could be a continuum of one entity. This review was designed primarily to compare neuropathological findings in different types of ALS relative to their characteristic locations as well as the immunoreactivity of the inclusions, and thus, foster a better understanding of the immunoreactivity, distribution, and morphology of the pathological deposits in relation to genetic mutations, which can be useful in specifying the final diagnosis.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Matej, Radoslav $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, 140 00 Prague, Czech Republic $u Department of Pathology, First Faculty of Medicine, Charles University, General University Hospital, 128 00 Prague, Czech Republic $u Department of Pathology, Third Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, 100 00 Prague, Czech Republic
773    0_
$w MED00195450 $t Diagnostics (Basel, Switzerland) $x 2075-4418 $g Roč. 11, č. 8 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34441299 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013134004 $b ABA008
999    __
$a ind $b bmc $g 1708257 $s 1144771
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 8 $e 20210729 $i 2075-4418 $m Diagnostics $n Diagnostics $x MED00195450
GRA    __
$a 00064165 $p MH CZ - DRO: Conceptual Development of Research Organization, the General University Hospital, Prague
GRA    __
$a 00064190 $p MH CZ - DRO: Conceptual Development of Research Organization, the Thomayer University Hospital, Prague
GRA    __
$a NV19-04-00090 $p the Grants Agency of the Ministry of Health
GRA    __
$a NV18-04-00179 $p the Grants Agency of the Ministry of Health
GRA    __
$a GAUK 142120 $p Univerzita Karlova v Praze
GRA    __
$a Project Progress Q27/LF1 $p Univerzita Karlova v Praze
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace